Searched for
LIRAGLUTIDE LAUNCH UK
Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and WegovyBiocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canad...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon ChiefKiran Mazumdar-Shaw of Biocon aims to consolidate, accelerate biosimilar business, and reduce debt after Viatris acquisition in FY25. Mazum...
- Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in IndiaDoctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resor...
- Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivotWeight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...
Load More
